Entero Healthcare Solutions
Entero Healthcare delivered a strong Q3 FY26 with revenue of ₹1,771 crore (+26% YoY) and EBITDA of ₹68 crore (+36% YoY), driven by organic growth of 17.1% and contributions from recent medtech acquisitions.
Entero Healthcare Solutions vs Akums Drugs & Q3 FY26
Side-by-side earnings comparison across verified financials, sentiment, risks, and management commentary.
Akums Drugs &
Akums delivered a strong Q3 FY26 with operating revenue of ₹1,160 crore (+14.8% YoY) and EBITDA of ₹147 crore (+21% YoY), driven by 16% volume growth in CDMO and recovery in international branded formulations.
Result Snapshot
Revenue₹1,707 Cr₹1,160 Cr
PAT₹34 Cr₹68 Cr
EBITDA Margin4%12.7%
Sentimentbullishbullish
Key Quotes
We are on track to deliver our full year guidance.
Our healthy operating performance was characterized by strong execution across multiple key segments. CDMO registered a healthy topline growth of more than 16% driven by strong volumes.